舍尼通治疗慢性非细菌性前列腺炎的临床研究

目的 评价舍尼通(Prostat)治疗慢性非细菌性前列腺炎(CNP)的有效性及安全性。方法 采用多中心开放临床试验方法，对115例慢性非细菌性前列腺炎患者进行为期8周的观察。口服舍尼通每天2次，每次1片(含70mg水溶性提取物P5及4mg脂溶性提取物EAl0)。结果 治疗后4周和8周，患者国际慢性前列腺炎症状评分(NIH-CPSI)总分分别较治疗前平均降低7．1(29．5％)和11．9(49．4％)，症状尺度评分分别较治疗前平均降低5．0(32．1％)和8．2(52．5％)，生活质量评分分别较治疗前平均降低2．1(24．6％)和3．7(43．9％)，前列腺液中WBC计数分别较治疗前平均降低8．8个／HP(39．3％)和13．9个／HP(61．9％)。治疗8周后总有效率82．1％。全组病例观察过程中未发现任何与药物有关的不良反应。结论 舍尼通可明显改善慢性非细菌性前列腺炎患者的疼痛不适症状和排尿症状，改善生活质量，减少前列腺液中的WBC计数，治疗效果确切，耐受性良好。

Clinical study with prostat for treatment of chronic nonbacterial prostatitis

Objective To evaluate the efficacy and safety of prostat in the treatment of chronic nonbacterial prostatitis (CNP). Methods A multicentral open clinical trial was conducted.A total of 115 CNP patients were enrolled in the trial.For each patient 1 tablet of prostat (70 mg P5+4 mg EA10) was orally administered twice a day. Results After 4- and 8- week therapy,NIH-CPSI overall scores were averagely decreased 7.1 (29.5%) and 11.9 (49.4%),respectively.Symptom rating scores were averagely decreased 5.0 (32.1%) and 8.2 (52.5%),respectively.Quality of life scores were averagely decreased 2.1 (24.6%) and 3.7 (43.9%),respectively.WBC counts in prostate massage fluid were averagely decreased 8.8/HP (39.3%) and 13.9/HP (61.9%),respectively.The total effective rate was 82.1% after 8 week therapy.No adverse reaction associated with medication was observed. Conclusions Prostat is effective and safe in relieving the subjective symptoms and improving the objective evaluation in the treatment of CNP patients.